证券代码：301093 证券简称：华兰股份 公告编号：2025-097 江苏华兰药用新材料股份有限公司 2、会议以 7 票同意、2 票反对、0 票弃权，审议通过了《关于公司投资设 立全资子公司的议案》。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）上披露的《关 于公司投资设立全资子公司的公告》。 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）第 六届董事会第六次会议通知于 2025 年 9 月 22 日以邮件、电话等方式向各位董 事发出，会议于 2025 年 9 月 26 日以现场会议结合通讯形式召开。本次会议由 公司董事长华一敏先生召集并主持，应出席会议的董事 9 人，实际出席会议的 董事 9 人，其中华国平先生、崔珂女士、姚茗芳女士、单体超先生、陈岗先生、 刘力先生、侯绪超先生以通讯表决方式出席本次董事会会议，公司高级管理人 员列席了会议。本次会议的召集、召开及表决符合《公司法》等有关法律、法 规、规范性文件 ...

关于调整公司组织架构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2025 年 9 月 26 日，江苏华兰药用新材料股份有限公司（以下简称"公司"） 第六届董事会第六次会议审议通过了《关于调整公司组织架构的议案》。根据公 司战略发展需求及实际经营情况，为进一步完善公司治理结构，优化管理流程， 提高公司管理水平和运营效率。董事会同意公司对组织架构进行优化调整，调 整后的公司组织架构图详见附件。 特此公告。 证券代码：301093 证券简称：华兰股份 公告编号：2025-098 江苏华兰药用新材料股份有限公司 江苏华兰药用新材料股份有限公司董事会 2025 年 9 月 26 日 附件 江苏华兰药用新材料股份有限公司组织架构图 ...

Group 1 - On September 25, Hualan Co., Ltd. experienced a slight increase of 0.11% in stock price, with a trading volume of 382 million yuan [1] - The financing data for Hualan on the same day showed a financing purchase amount of 48.17 million yuan and a net financing purchase of 8.96 million yuan, with a total financing and securities balance of 513 million yuan [1] - The financing balance of Hualan accounts for 6.98% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, Hualan had 15,300 shareholders, a decrease of 1.05% from the previous period, while the average circulating shares per person increased by 38.20% to 7,901 shares [2] - For the first half of 2025, Hualan reported an operating income of 309 million yuan, representing a year-on-year growth of 8.82%, and a net profit attributable to shareholders of 43.73 million yuan, up 18.27% year-on-year [2] Group 3 - Hualan has distributed a total of 238 million yuan in dividends since its A-share listing, with 144 million yuan distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders of Hualan saw the exit of Changjiang Intelligent Manufacturing Mixed Fund from the list [3]

Market Overview - On September 24, the medical device sector rose by 0.1% compared to the previous trading day, with Hualan Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Top Performers - Hualan Co., Ltd. (301093) closed at 44.74, up 10.20% with a trading volume of 120,900 shares and a transaction value of 526 million yuan [1] - Huitai Medical (688617) closed at 321.65, up 6.86% with a trading volume of 21,200 shares [1] - Jinhao Medical (872925) closed at 31.15, up 6.68% with a trading volume of 17,400 shares [1] Other Notable Stocks - Dongxing Medical (301290) closed at 27.96, up 5.35% with a trading volume of 34,600 shares [1] - Dabo Medical (002901) closed at 55.06, up 5.02% with a trading volume of 42,100 shares [1] - Maike Aodi (300341) closed at 18.79, up 4.97% with a trading volume of 373,300 shares [1] Fund Flow Analysis - The medical device sector experienced a net outflow of 12.47 million yuan from institutional investors, while retail investors saw a net inflow of 24.3 million yuan [2] - The overall fund flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Fund Flow - Maike Aodi (300341) had a net inflow of 94.47 million yuan from institutional investors, but a net outflow of 85.20 million yuan from retail investors [3] - Huo Jing Biological (688068) saw a net inflow of 58.76 million yuan from institutional investors, with retail investors also withdrawing funds [3] - Dabo Medical (002901) had a net inflow of 33.73 million yuan from institutional investors, while retail investors experienced a net outflow [3]

Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a 5% increase in stock price, reaching 42.63 yuan per share, with a total market capitalization of 7 billion yuan [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%) and conventional rubber stoppers (48.50%) [1] - The company was established on June 4, 1992, and went public on November 1, 2021 [1] Group 2 - According to data, Dachen Fund has a significant holding in Hualan Co., Ltd., with its Dachen Growth Mixed Fund holding 620,000 shares, accounting for 3.29% of the fund's net value [2] - The Dachen Growth Mixed Fund has achieved a year-to-date return of 23.45% and a one-year return of 46.55% [2] - The fund manager, Zou Jian, has been in position for 4 years and 243 days, with the fund's total asset size currently at 1.086 billion yuan [2]

Group 1 - The stock price of Hualan Biological Engineering reached a historical high, increasing by 4.85% to 42.57 yuan, with a trading volume of 2.7837 million shares and a transaction value of 115 million yuan, resulting in a turnover rate of 1.77% [2] - The latest total market capitalization of Hualan Biological is 6.99 billion yuan, with a circulating market capitalization of 6.681 billion yuan [2] - The pharmaceutical and biotechnology industry, to which Hualan belongs, has an overall increase of 0.48%, with 377 stocks rising, including notable gainers such as Sunflower, Ganli Pharmaceutical, and Xinlitai, which rose by 15.13%, 8.97%, and 6.83% respectively [2] Group 2 - The latest margin trading data shows that Hualan's margin balance is 490 million yuan, with a financing balance of 490 million yuan, which has increased by 42.599 million yuan over the past 10 days, reflecting a growth of 9.52% [2] - According to the company's semi-annual report, Hualan achieved an operating income of 309 million yuan in the first half of the year, representing a year-on-year growth of 8.82%, and a net profit of 43.7321 million yuan, which is an increase of 18.27% year-on-year, with basic earnings per share of 0.2700 yuan and a weighted average return on equity of 1.93% [2]

Group 1 - The core point of the article is that Hualan Co., Ltd. has launched an employee stock ownership plan for 2025, aiming to raise a total of no more than 56.85 million yuan, involving no more than 2.92 million shares, which accounts for approximately 1.78% of the company's total share capital [1] - The plan includes participation from no more than 260 senior management and key personnel, with profit growth targets set for the years 2025, 2026, and 2027, requiring net profit increases of 50%, 105%, and 155% respectively compared to 2024 [1] - The company reported a revenue of 309 million yuan in the first half of 2025, representing a year-on-year growth of 8.82%, and a net profit attributable to shareholders of 43.73 million yuan, up 18.27% year-on-year [1] Group 2 - The increase in net profit is primarily attributed to a rise in revenue, which led to an increase in gross profit by 9.73 million yuan, alongside a reduction in sales expenses by 3.20 million yuan due to optimized sales policies [1] - The company has been actively expanding its market, with revenue from its core product, film-coated rubber stoppers, increasing by 9.28%, and the gross margin improving by 2.16 percentage points to 53.62% [1] - Revenue from conventional rubber stoppers grew by 7.94%, although the gross margin decreased by 1.64 percentage points to 25.64% [1]

Core Viewpoint - Hualan Co., Ltd. announced an employee stock ownership plan for 2025, aiming to raise a total of 56.85 million yuan, including reserved shares [1] Summary by Sections Employee Stock Ownership Plan - The employee stock ownership plan has a maximum fundraising target of 56.85 million yuan, with shares being the unit of subscription, requiring employees to subscribe in whole numbers [1] - The reward fund is capped at 24.85 million yuan, and the incentive fund will be accounted for as an expense based on the accrual basis [1] - The shares for this plan will be sourced from the company's repurchased A-share common stock held in a dedicated repurchase account [1] Share Distribution - The plan has been approved by the company's shareholders, and the shares in the repurchase account will be transferred to the employee stock ownership plan through legally permitted methods such as non-trading transfers [1] - The total number of shares held by the employee stock ownership plan will not exceed 2.92 million shares, which represents approximately 1.78% of the company's current total share capital [1]

江苏华兰药用新材料股份有限公司 2025 年员工持股计划 （草案） 证券简称：华兰股份 证券代码：301093 江苏华兰药用新材料股份有限公司 2025 年员工持股计划 （草案） 二〇二五年九月 1 江苏华兰药用新材料股份有限公司 2025 年员工持股计划 （草案） 公司声明 本公司及董事会全体成员保证本员工持股计划不存在任何虚假记载、误导 性陈述或重大遗漏，并对其内容真实性、准确性、完整性承担个别和连带的 法律责任。 2 江苏华兰药用新材料股份有限公司 2025 年员工持股计划 （草案） 风险提示 本部分内容中的词语简称与"释义"部分保持一致。 一、江苏华兰药用新材料股份有限公司 2025 年员工持股计划需经公司股 东会审议通过后方可实施，本员工持股计划能否获得公司股东会批准，存在不 确定性。 二、本员工持股计划遵循依法合规、自愿参与、风险自担原则，若员工认 购资金不足，本员工持股计划存在低于预计规模的风险。 三、有关本员工持股计划的具体资金来源、实施方案等属初步结果，能否 完成实施，存在不确定性。 四、本员工持股计划中有关公司业绩考核指标的描述不代表公司的业绩预 测，亦不构成业绩承诺。 五、公司后续将根据 ...

江苏华兰药用新材料股份有限公司 董事会关于 2025 年员工持股计划（草案）合规性的说明 江苏华兰药用新材料股份有限公司（以下简称"公司"）根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）以及《关于上市公司实施员工持股计划试点的指导意见》（以下 简称"《指导意见》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》（以下简称"《创业板上市公司规范运作》"）等有关法律 法规、规范性文件及《公司章程》的有关规定，制定了《2025 年员工持股计划 （草案）》（以下简称"本次员工持股计划"），董事会现就本次员工持股计划符合 《指导意见》等相关规定说明如下： 一、公司不存在《指导意见》《创业板上市公司规范运作》等法律、法规规 定的禁止实施员工持股计划的情形，公司具备实施员工持股计划的主体资格。 二、本次员工持股计划内容符合《指导意见》《创业板上市公司规范运作》 等有关法律、法规及规范性文件的规定，公司推出本次员工持股计划前，已通过 职工代表大会充分征询了员工意见。 三、本次员工持股计划关联董事已根据相关规定回避表决，公司审议本次 ...